Ceapro (TSXV:CZO) Tax Provision : C$1.20 Mil (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Ceapro Tax Provision?

Ceapro's tax provision for the three months ended in Dec. 2023 was C$0.49 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was C$1.20 Mil.

Ceapro Tax Provision Historical Data

The historical data trend for Ceapro's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Tax Provision Chart

Ceapro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

0.07

-1.38

1.20

Ceapro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tax Provision	Get a 7-Day Free Trial															0.05	0.11	0.32	0.29	0.49

Ceapro Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.20 Mil.

Ceapro (TSXV:CZO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

CRPOF:USA

Address

7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2

Website

https://www.ceapro.com

Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines